Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...

One of the UK’s most senior radiotherapy experts has spoken publicly for the first time about living with incurable cancer.

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The Government is “looking carefully” at introducing routine screening for prostate cancer as developments in technology are ...

Movember is proud to announce its latest prostate cancer investment of over $4.9 million. Eighteen grants (16 proposals and 2 ...

The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.

Following a change in screening guidelines, the incidence went up across the state, even more than it has nationally.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.